Tikva Allocell Secures $8 Million Series A Financing to Advance Engineered Off-the-Shelf Cell Therapies for Solid Tumors July 28, 2026
Positive Updated Ph 2 Data and Expansion of Safusidenib Clinical Program with Two New Studies to Explore Broad Spectrum of IDH1-Mutant Glioma Announced July 28, 2026
Lupin spins out two oncology programs LNP7457 (PRMT5) and LNP8701 (SOS1) into Kaveri Therapeutics July 28, 2026
TECVAYLI + TALVEY reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line R/R multiple myeloma July 28, 2026
Enhertu + pertuzumab recommended for approval in the EU by CHMP in 1L HER2-positive metastatic breast cancer July 28, 2026
BeOne Medicines Expands U.S. Manufacturing with More Than $1 Billion Investment to Advance Cancer Medicines July 28, 2026
First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial and Reports Durable Response Rate in Advanced B-Cell NHL July 28, 2026
Sonesitatug vedotin demonstrated statistically significant OS improvement in 2L+ CLDN18.2-positive advanced gastric/GEJ cancers July 28, 2026
FDA accepts NDA for Daraxonrasib for Review for Previously Treated Metastatic Pancreatic Cancer July 28, 2026
Tempest Announces Development Collaboration with Senlang Biotechnology for CD7-Targeted Next-Gen In Vivo CAR-T TPST-4003 July 28, 2026
CTA and supply agreement between Phanes & Merck to evaluate spevatamig, KEYTRUDA & chemo combo for treatment of biliary tract cancer expanded July 28, 2026
Kairos Pharma Announces Strategic Collaboration with Bayer to Enhance XOFIGO Activity in Metastatic Prostate Cancer July 28, 2026
Arcus Biosciences Announces Clinical Supply Agreement with AVEO Oncology to Evaluate Casdatifan-Tivozanib Combination for Advanced Kidney Cancer Patients July 28, 2026
Arcus Biosciences and Summit Therapeutics Enter into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer July 28, 2026
Enrollment completed in Ph 1 Dose Escalation Study of IPH4502 in patients with advanced solid tumors July 28, 2026
Last Patient, Last Visit in LAM561 Ph 2b/3 Trial for Newly Diagnosed GBM Patients Announced July 28, 2026
Enrollment completed in Ph 2 trial of spevatamig + chemo for the 1L metastatic pancreatic ductal adenocarcinoma July 28, 2026
Confirmed Durable Partial Response in Ph 1 Trial of RAD204 in Patients with Advanced Solid Tumors Post-Immunotherapy July 28, 2026
FAILED TRIAL: Ph 3 EPCORE® DLBCL-1 Trial of Epcoritamab in Patients with R/R DLBCL failed to meet primary OS endpoint July 28, 2026
